Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1994-03-15
1996-01-02
Bawa, Raj
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424451, 424484, 514304, 514557, 514161, 514813, A61K 928
Patent
active
054806518
ABSTRACT:
A method for relieving craving in a nicotine-habituated patient and a composition for treating the patient is provided. The composition administered has a non-specific acetylcholine agonist and a muscarinic agonist. A particularly preferred composition for relieving craving takes the form of a tablet where the first component is a water soluble physostigmine and the second component is a water soluble scopolamine. Patients treated have reported a slight increase in alertness and a diminished craving for nicotine.
REFERENCES:
patent: 4242344 (1980-12-01), Lumma
patent: 4278678 (1981-07-01), Madison et al.
patent: 4555397 (1985-11-01), Bachynsky
patent: 4778677 (1988-10-01), Ebbesen
patent: 4788189 (1988-11-01), Glazer
patent: 4835162 (1989-05-01), Abood
patent: 4940585 (1990-07-01), Hapworth et al.
patent: 4952586 (1990-08-01), Morris et al.
patent: 4966916 (1990-10-01), Abood
patent: 5026897 (1991-06-01), Chiang et al.
patent: 5035897 (1991-07-01), Ayer et al.
patent: 5077289 (1991-12-01), Glamkowski et al.
patent: 5102666 (1992-04-01), Acharya
patent: 5153193 (1992-10-01), Flanagan et al.
patent: 5171750 (1992-12-01), Brossi et al.
patent: 5206371 (1993-04-01), Powers et al.
patent: 5231093 (1993-07-01), Flanagan et al.
patent: 5260452 (1993-11-01), Glamkowski et al.
patent: 5264442 (1993-11-01), Effland et al.
Glassman et al., "Cigarette Craving, Smoking Withdrawal, and Clonidine", Science, 226, (1984) pp. 864-866.
Vidal et al., "Pharmacological Profile of Nicotinic Acetylcholine Receptors in The Rat Prefrontal Cortex," Neuroscience, vol. 29, No. 2, (1989), pp. 261-270.
Kaiser et al., "Cholinergic Agents", Neurotransmissions, vol. III, No. 2, (1987), pp. 1-5.
Reynolds (editor), Martindale: The Extra Pharmacopoeia, 29th edition, London: The Pharmaceutical Press, (1989), pp. 522, 534-536, 1328, 1333-1335, and 1594-1595.
Solana et al., "Comparing the Efficacy of Physostigmine Pretreatment in Combination with Scopolamine versus Artane Against Soman Challenge," Report USAMRICD-TR-88-19; Order No. AD-A201608 (1989).
Hrbek et al., "On the Acute Effects of Scopolamine (0.6 mg), Physostigmine (1.0 mg), and a Complex Combination of Both the Drugs on the Higher Nervous Activity in Man," Acta Univ. Palacki. Olomuc., Fac. Med., 85, (1978) 281-327.
Harris et al., "Protection Against Diisopropylfluorophosphate Intoxication by Pyridostigmine and Physostigmine in Combination with Atropine and Mecamylamine," Arch Pharmacol, 327 (1984), pp. 64-69.
Stitcher et al., "Effects of Pyridostigmine and Cholirolytics on Cholisesterase and Acetylcholine in Soman Poisoned Rats," Drug and Chemical Toxicology, 1(4) (1978), pp. 355-362.
Cassone et al., "Effects of Combinations of Arecoline and Atropine on Mouse Motor Activity," Prog. Neuro-Psycholpharmacol. & Biol. Psychiat., 14 (1990), pp. 83-90.
Eriksen et al., "Effects on Muscarinic Receptors of Various Agents in Reversal of NeuropMuscular Blockade . . . , " Chemical Abstracts, vol. 89, No. 23, Item 191258k.
Rose and Levin, "Concurrent Agonist-Antagonist Administration for the Analysis and Treatment of Drug Dependence," Pharmacology Biochemistry and Behavior, 41, pp. 219-226, 1991.
Iijima et al., "Phenserine: A Physostigmine Derivative that is a Long-Acting Inhibitor of Cholinesterase and Demonstrates a Wide Dose Range for Attenuating a Scopolamine-Induced Learning Impairment of Rats in a 14-unit T-Maze," Psychopharmacology, 112, pp. 415-420, 1993.
Smith et al., "Methylatropine Blocks the Central Effects of Cholinergic Antagonists," Behavioural Pharmacology, 5, pp. 167-175, 1994.
Chem. Abst., vol. 116, No. 1, Item 656g.
Bawa Raj
Regents of the University of California
LandOfFree
Composition and method for treating nicotine craving in smoking does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating nicotine craving in smoking , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating nicotine craving in smoking will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-233535